Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
Earnings Data
Report Date
May 13, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.43Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum: positive Phase III results, clear FDA pre‑NDA agreement, an imminent rolling NDA submission, advanced U.S. partner discussions, and a strategic technology expansion (Kynatrix and GLP‑1 program). These operational highlights position the company for a potential transformative 2026. However, material lowlights include a limited cash runway into H2 2026, rising operating expenses and an increased full‑year net loss, as well as dependence on partnership execution and a likely multi‑month adoption curve post‑approval. Overall the positive regulatory and clinical milestones significantly outweigh the financial and execution risks, but those risks will require near‑term resolution.Company Guidance
Phase III Success and Clinical Validation
Completed SHIELD II Phase III trial; D-PLEX100 met its primary endpoint and all key secondary endpoints, demonstrating a meaningful reduction in surgical site infections. External clinical engagement (KOL webinar with Dr. Steven D. Wexner) reinforced trial design and real-world relevance.
Regulatory Progress — FDA Pre‑NDA Feedback and Rolling NDA Plan
Received positive written feedback from the FDA after the pre‑NDA meeting: agency agreed the existing clinical data package is adequate to support an NDA and supported a rolling NDA submission. Company expects to begin rolling submission by end of Q1 2026 and anticipates an accelerated review (priority/6‑month review due to Fast Track / Breakthrough designations).
Advanced U.S. Partnership Discussions
Moved into advanced, operationally detailed U.S. partnership discussions with potential hospital-focused commercial partners; due diligence progressing and discussions driven by partners with hospital and surgical suite capabilities.
Technology & Pipeline Expansion — Kynatrix and GLP‑1 Program
Formally introduced Kynatrix as next‑generation controlled-release/delivery platform (collects expanded IP and capabilities beyond PLEX). Launched an ultra‑long‑acting GLP‑1 receptor agonist preclinical program targeting ~60+ day exposure, representing a systemic/metabolic expansion of the platform and a potential early partnering opportunity.
Corporate & Commercial Readiness
Refreshed corporate brand and website to support commercialization orientation. Appointed Brooke Story as Chair of the Board (experience at Becton Dickinson and Medtronic) to guide strategic commercialization and partner engagement.
Financial Actions and Expense Tailoring
Q4 2025 R&D expense decreased to $6.2M from $7.0M year‑ago (≈11.4% decrease) reflecting completion of Phase III and shift to regulatory activities. Subsequent warrant exercises generated $3.7M gross proceeds post‑quarter, and company reports $12.9M cash and short‑term deposits as of Dec 31, 2025; management believes cash resources sufficient to fund operations into H2 2026.
PYPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PYPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | $4.68 | $4.62 | -1.28% |
Nov 12, 2025 | $3.76 | $3.75 | -0.27% |
Aug 13, 2025 | $3.42 | $3.49 | +2.05% |
May 14, 2025 | $2.71 | $2.90 | +7.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PolyPid Ltd. (PYPD) report earnings?
PolyPid Ltd. (PYPD) is schdueled to report earning on May 13, 2026, Before Open (Confirmed).
What is PolyPid Ltd. (PYPD) earnings time?
PolyPid Ltd. (PYPD) earnings time is at May 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PYPD EPS forecast?
PYPD EPS forecast for the fiscal quarter 2026 (Q1) is -0.43.